1. Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis

   • James W. T. Yates
   • Shampa Das
   • John Kemp

   Original Paper 23 September 2012 Pages: 591 - 599

   

2. Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

   • K. Ito
   • M. M. Hutmacher
   • B. W. Corrigan

   Original Paper 19 September 2012 Pages: 601 - 618

   

3. Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease

   • Jace C. Nielsen
   • Matthew M. Hutmacher
   • Jakob Ribbing

   Original Paper 23 September 2012 Pages: 619 - 634

   

4. A population pharmacokinetic model for the complex systemic absorption of ropivacaine after femoral nerve block in patients undergoing knee surgery

   • François Gaudreault
   • Pierre Drolet
   • France Varin

   Original Paper 30 September 2012 Pages: 635 - 642

   

5. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

   • Dhaval K. Shah
   • Nahor Haddish-Berhane
   • Alison Betts

   Original Paper 15 November 2012 Pages: 643 - 659

   

6. Optimised protocol design for the screening of analgesic compounds in neuropathic pain

   • A. Taneja
   • J. Nyberg
   • O. Della Pasqua

   Original Paper 30 November 2012 Pages: 661 - 671

   

7. Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain

   • A. Taneja
   • J. Nyberg
   • O. Della Pasqua

   Original Paper 30 November 2012 Pages: 673 - 681

   

8. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer

   • Lubna Abuqayyas
   • Joseph P. Balthasar

   Original Paper 27 November 2012 Pages: 683 - 710

   

9. Applications of minimal physiologically-based pharmacokinetic models

   • Yanguang Cao
   • William J. Jusko

   Original Paper 23 November 2012 Pages: 711 - 723

   

10. Letter to the editor regarding: “A reduction in between subject variability is not mandatory for selecting a new covariate”

    • Mats O. Karlsson
    • Martin Bergstrand

    Commentary 30 September 2012 Pages: 725 - 726

11. Reply to the editor of Journal of Pharmacokinetics and Pharmacodynamics

    • Chakradhar V. Lagishetty
    • Pavan Vajjah
    • Stephen B. Duffull

    Commentary 02 October 2012 Pages: 727 - 727